Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024312 (lymphopenia)
 4,859 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Immune responses to heat-killed Brucella abortus strain 19 and to ovalbumin were compared in 15 fluke-infected and 15 fluke-free Friesian heifers. B abortus was injected 16 weeks and ovalbumin 19 weeks after the oral administration of 1000 metacercariae of Fasciola hepatica. Agglutinating antibody responses to B abortus were similar in both groups. Immediate type hypersensitivity to ovalbumin was apparently suppressed in fluke-infected animals when assessed by active and passive cutaneous anaphylaxis two weeks after sensitisation. However, when assessed by Schultz-Dale responses of intestine, in vitro, 36 weeks after sensitisation there was no difference between the groups. The heifers were subsequently given live Salmonella dublin intravenously. The fluke-infected animals which became carriers of S dublin had the most persistently elevated titres of agglutinating antibodies in their sera and the highest incidence of immediate-type hypersensitivity, as assessed by Schultz-Dale responses of intestine, but the weakest cutaneous delayed hypersensitivity reactions to S dublin. The latter might have been related to lymphopenia which developed after fluke infection. The increased susceptibility of fluke-infected cattle to S dublin cannot be attributed to impaired agglutinin responses but may result from effects on cell-mediated mechanisms.
 ...
PMID:Immunological responses of fluke-infected and fluke-free cattle to Salmonella dublin and other antigens. 12 May 72

R24 is a mouse IgG3 monoclonal antibody that reacts with the ganglioside GD3 expressed by melanoma cells and other cells of neuroectodermal origin (e.g. adrenal medulla). Antitumour activity of R24 was demonstrated in initial phase I and pilot trials, but treatment was limited by urticaria at cumulative doses of 400 mg/m2. A trial exploring intensification of the dose of R24 was conducted in eight patients. Planned doses of R24 antibody were 800 and 1200 mg/m2 over 6-8 days by continuous i.v. infusion. All patients received concomitant therapy with hydroxyzine hydrochloride and cimetidine to minimize urticaria. One patient developed anaphylaxis, after which no further therapy was given. All patients developed peripheral blood lymphopenia and marked decreases in serum complement values during treatment, suggesting depletion of two possible effector mechanisms of the antitumour effects of R24. A vascular leak syndrome, manifested by weight gain, oedema and hypotension, was evident in seven patients during the initial 24-36 h of treatment. Serum sickness syndrome was observed in six of seven evaluable patients between days 5 and 8, coincident with the onset of the human anti-globulin response to R24. One patient given 1200 mg/m2 had a minor response (38% reduction in pelvic nodes) lasting 12 months. There was no detectable increase (by immunohistochemical staining) in deposition of R24 within tumour sites at doses used in this trial compared to that observed at doses of 240 and 400 mg/m2. The maximum tolerated dose was 800 mg/m2. Dose-limiting toxicity was manifest as reversible hypertension with end-organ symptoms (chest pain or visual field defects) in patients treated with a dose of 1200 mg/m2.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma. 129 83